1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Cancer Drug News 21 DECEMBER 2015

Cancer Drug News 21 DECEMBER 2015

  • December 2015
  • -
  • Espicom Business Intelligence
  • -
  • 12 pages

Industry Trend Analysis - Novartis Maintaining CAR-T Lead
Industry Brief - FDA Accepts Ibrance sNDA For HR+/HER2- Metastatic Breast Cancer
Industry Brief - NICE Deems Kadcyla Price Too High For Routine NHS Funding
Industry Trend Analysis - Commercial Opportunities In Breast Cancer Remain
Industry Trend Analysis - Precision Medicine To Evolve Through Multi-Gene Signatures
Industry Brief - Seattle Genetics Highlights Positive Adcetris Data At ASH 2015
Industry Brief - Ninlaro Now Available In US
Industry Brief - Soligenix Initiates SGX301 Phase III CTCL Trial
Industry Brief - Alecensa Approved In US For ALK-Positive NSCLC
Industry Brief - Agensys/Bellicum Sign Licensing Deal To Develop Cell Therapies Targeting PSCA
Industry Brief - FDA Grants TapImmune Ovarian Cancer Vaccine ODD
Industry Brief - ArQule's Cholangiocarcinoma Candidate Gains ODD
Industry Brief - CRS-207/GVAX Pancreas Granted ODD For Pancreatic Cancer
Industry Brief - Axalimogene Filolisbac Granted ODD For Anal Cancer
Industry Brief - FDA Lifts Advaxis Clinical Hold
Industry Brief - WuXi/MedImmune Form Strategic Alliance To Expedite Biologics Portfolio in China
Industry Brief - FDA Approves Expanded Age Indication For Gardasil 9 In Males
Industry Brief - Amgen Reacquires Rights To Prolia/Xgeva/Vectibix From GSK
Industry Trend Analysis - CEE Represents Opportunity For Cancer Drugmakers
Industry Brief - Neon/BMS Enter Clinical Trial Collaboration
Industry Brief - EMA Commences Evaluation Of Gedeon Richter's Pegfilgrastim
Industry Brief - Swissmedic Approves Akynzeo For CINV
Industry Brief - FDA Approves Wellstat's Vistogard To Treat 5-FU/Capecitabine Chemotherapy Overdoses
Industry Brief - Kyras Therapeutics Launches

Table Of Contents

Cancer Drug News 21 DECEMBER 2015

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests,  Opport

2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests, Opport

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-company survey from VPGMarketResearch.com contains 1,650 pages and 890 tables. The report provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein ...

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.